SHANGHAI – Beijing newcomer Canbridge Life Sciences Ltd. has partnered with emerging nanotech specialist Azaya Therapeutics Inc., of San Antonio, to develop non-small-cell lung cancer (NSCLC) treatment ATI-1123 in China and North Asia.
SHANGHAI – Beijing newcomer Canbridge Life Sciences Ltd. has partnered with emerging nanotech specialist Azaya Therapeutics Inc., of San Antonio, to develop non-small-cell lung cancer (NSCLC) treatment ATI-1123 in China and North Asia.
SHANGHAI – Two Chinese biopharmaceutical firms have been added to an ongoing corruption probe in China that has already expanded to cover several multinationals. They include Chia Tai Tianqing Pharmaceutical Group, which is majority owned by Sino Biopharmaceutical Ltd., and privately held Gan & Lee Biotechnology Co. Ltd.
SHANGHAI – A joint venture between a Chinese and a Swiss company has launched Phase III trials for a botanical drug to treat inflammatory bowel disease.
SHANGHAI – Hu Fang was the poster boy for China’s potential in biomedicine back in 2005. At the head of Shanghai Sunway Biotech Co. Ltd., he saw the need to bring innovative drug development to China and found a truly entrepreneurial method to do it: Take a molecule patented in the U.S. that had been gathering dust after an aborted early stage clinical trial and develop it for the China market.
SHANGHAI – A joint venture between a Chinese and a Swiss company has launched Phase III trials for a botanical drug to treat inflammatory bowel disease.
The year 2013 is emerging as a banner one for East-West partnerships among biotech companies. More Western biopharmas with innovative capability and patented molecules in need of development are partnering with local companies in China to tap the potential of the market.
SHANGHAI – Four multinational pharmaceutical firms have been hit with allegations of bribery in China since the Glaxosmithkline plc scandal first broke almost two months ago. China’s State Administration for Industry & Commerce (SAIC) has announced a three-month probe that will target pharmaceutical and medical device sales.
SHANGHAI – Four multinational pharmaceutical firms have been hit with allegations of bribery in China since the Glaxosmithkline plc scandal first broke almost two months ago. China’s State Administration for Industry & Commerce (SAIC) has announced a three-month probe that will target pharmaceutical and medical device sales.
